TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Nadine M TungMark E RobsonSteffen VentzCesar A Santa-MariaRita NandaP Kelly MarcomPayal Deepak ShahTarah J BallingerEddy Shih-Hsin YangShaveta VinayakMichelle E MeliskoAdam M BrufskyMichelle DeMeoColby JenkinsSusan M DomchekAlan D' AndreaNancy U LinMelissa E HughesLisa Anne CareyNikhil WagleGerburg M WulfIan E KropAntonio C WolffEric P WinerJudy E GarberPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
PARP inhibition is an effective treatment for patients with MBC and gPALB2 or sBRCA1/2 mutations, significantly expanding the population of patients with breast cancer likely to benefit from PARPi beyond gBRCA1/2 mutation carriers. These results emphasize the value of molecular characterization for treatment decisions in MBC.